RT Journal Article
SR Electronic
T1 Developing a core outcome set for interventions in people with mild cognitive impairment: study protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.05.24309989
DO 10.1101/2024.07.05.24309989
A1 Gabb, Victoria Grace
A1 Harding, Sam
A1 McNair, Angus
A1 Clayton, Julie
A1 Barrett-Muir, Winsome
A1 Richardson, Alan
A1 Woodward, Natalie
A1 Alderman, Sophie
A1 Dooley, Jemima
A1 Webb, Joseph
A1 Rudd, Sarah
A1 Coulthard, Elizabeth
A1 Turner, Nicholas
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.05.24309989.abstract
AB Introduction There is no standardised national guidance on clinical management for people living with mild cognitive impairment (MCI) and therapeutic interventions are limited. Understanding what outcomes are important and meaningful to people living with MCI and developing a core outcome set for research and clinical practice will improve the impact of clinical research and contribute towards developing effective care pathways for MCI. This study aims to develop a core outcome set (COS) for adults living with MCI intended for use in interventional and clinical settings.Methods and analysis The COS will be developed using a five-stage study design: (1) systematic literature search; (2) qualitative interviews; (3) evidence synthesis from stage 1 and 2; (4) two-round Delphi survey; (5) consensus meetings. First, we will conduct an umbrella review of existing MCI interventional studies and extract a list of outcomes. Qualitative interviews will be held with key stakeholders including individuals living with MCI, friends and family, and relevant professionals to identify further outcomes considered important. Outcomes from the review and interviews will be synthesised into a “long list” of outcomes for potential inclusion in the COS. Two rounds of a Delphi surveys followed by a consensus meeting will be used to reach stakeholder consensus on which outcomes should be included in the final COS.Ethics and dissemination We have received ethical approval from London - Queen Square Research Ethics Committee (23/PR/1580). Patient and public involvement and engagement are central to developing the COS. The results will be disseminated via conferences, peer-reviewed publications, briefing notes to key agencies, to the public via social media and blog posts, and directly to stakeholders who participate in the project.Trial registration number Core Outcome Measures in Effectiveness Trials (COMET) Initiative 2117; PROSPERO registration: CRD42023452514.Strengths and limitationsTo our knowledge, this will be the first core outcome set developed to evaluate interventions for people with mild cognitive impairment (MCI).The study will use a multi-stage process including an umbrella review, qualitative interviews, Delphi surveys, and a consensus meeting to incorporate multidisciplinary stakeholder perspectives including those living with MCI and individuals who know, care for, work with, or provide services for people with MCI.Development and adoption of this COS is expected to enhance the value of research into MCI and clinical practice through encouraging transparent reporting of agreed meaningful outcomes to stakeholders.A limitation of this study is that recruitment sites will be based in England only. However, we will aim to recruit international stakeholders to participate in the study and the umbrella review will include international literature. Efforts will be made to include individuals at each qualitative stage with diverse experience, backgrounds, and demographics.There are many possible outcomes for inclusion in the COS and it may be difficult to reach consensus across stakeholders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is funded by the National Institute for Health and Care Research (NIHR) Research for Patient Benefit (NIHR204135).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee of London - Queen Square gave ethical approval for this work (23/PR/1580)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesParticipants will be asked if they consent to data sharing beyond use in the COS development. Anonymised data may be shared upon reasonable request from the authors if the request is in line with consent received from participants.